Evidence map›Paper›PMID 41105164›Full record

Observational studyCalcified tissue international2025

Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses.

Yi-Lin Chiu, Tsai-Yuan Hsieh, Yu-Juei Hsu, Tien-Yu Huang, Chang-Hung Liao, Meng-Chuan Lu, Fang-Chen Liu, Yi-Ting Chou, Chao-Feng Chang, I-Hsuan Huang and 5 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yi-Lin ChiuDepartment and Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University, Taipei, Taiwan.
Tsai-Yuan HsiehDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Yu-Juei HsuDivision of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
Tien-Yu HuangDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Chang-Hung LiaoDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Meng-Chuan LuDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Fang-Chen LiuDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Yi-Ting ChouDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Chao-Feng ChangDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
I-Hsuan HuangDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Bao-Chung ChenDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Hsuan-Hwai LinDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Yu-Lueng ShihDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
Yun-Ju YangDepartment of Neurological Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
Jung-Chun LinDivision of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, 325, Sec 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan. doc10506@gmail.com.ORCID http://orcid.org/0000-0001-5059-8766

Funding

Medical Affairs Bureau MAB-104-089Medical Affairs Bureau MAB-108-074Ministry of Science and Technology, Taiwan MOST 107-2314-B-016-001-Ministry of Science and Technology, Taiwan MOST 111-2314-B-016-046Ministry of Science and Technology, Taiwan NSTC111-2314-B-016 -019 -MY3Tri-Service General Hospital TSGH-C-108-074Tri-Service General Hospital TSGH-C99-167Tri-Service General Hospital TSGH-E-109220
6 · The paper itself

Abstract

Chronic hepatitis C (CHC) is a risk factor for hepatic osteodystrophy, increasing osteoporosis and fracture risks. While historical pegylated interferon/ribavirin (PEG-IFN/RBV) showed variable bone effects, the newer direct-acting antivirals' (DAAs) impact is less clear. This study compared these antiviral strategies' effects on bone metabolism in CHC patients through two separate analyses. First, we conducted a retrospective analysis of a prospectively collected observational cohort (n = 73) to assess longitudinal bone mineral density (BMD) and bone turnover marker (BTM) changes following PEG-IFN/RBV or DAA therapies. Second, to explore mechanisms, we analyzed two independent, publicly available peripheral blood mononuclear cell (PBMC) transcriptomic cohorts from CHC patients treated with PEG-IFN/RBV (GSE7123, n = 69) or an IFN-free DAA regimen (GSE51699, n = 8). Clinically, PEG-IFN/RBV induced a temporary lumbar spine BMD increase, then a post-treatment decline, and modulated BTMs. DAAs showed minimal BMD/BTM effects. PBMC transcriptomics revealed PEG-IFN/RBV responders showed downregulation of osteoclast precursor (OCP)-related gene sets and concurrent upregulation of osteoblast-related gene sets. DAAs had a minimal impact on these PBMC pathways. These findings demonstrate distinct effects of PEG-IFN/RBV and DAA therapies. PEG-IFN/RBV significantly modulates PBMC gene expression related to bone remodeling, potentially contributing to the complex clinical BMD changes, while DAAs appear largely bone-neutral. This highlights treatment-specific osteoporosis risk and surveillance needs in CHC survivors.

Indexed as

Antiviral AgentsBone and BonesHepatitis C, ChronicInterferonsAdultAgedBone DensityBone RemodelingFemaleHumansInterferon-alphaMaleMiddle AgedProspective StudiesRetrospective StudiesRibavirinAntiviral AgentsInterferon-alphaInterferonsRibavirinBone mineral densityChronic hepatitis CDirect-acting antiviralsInterferon therapyOsteoimmunologyTranscriptomics

Identifiers

PMID41105164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.